BDgene Technology

BDgene Therapeutics is a leading high-tech biopharmaceutical company in China, specializing in the development of gene therapy solutions for major diseases that were previously considered incurable. The company operates in the biopharmaceutical market, focusing on advanced gene editing and delivery technologies. BDgene's core clients include top-tier tertiary hospitals, international pharmaceutical companies, and research institutions. The business model revolves around the development and commercialization of gene therapy treatments, leveraging proprietary technologies such as the BDlenti Platform for lentiviral vector delivery and viroid mRNA VLP for gene editing. Revenue is generated through partnerships, licensing agreements, and clinical applications of their therapies. The company's advisory team comprises authoritative experts in gene therapy, clinicians, and executives from listed pharmaceutical companies, ensuring a robust and innovative approach to drug development.

Keywords: gene therapy, biopharmaceutical, lentiviral vectors, gene editing, CRISPR, viral keratitis, thalassemia, HSV-1, mRNA delivery, preclinical research.